Julianna Merten, PharmD, BCPS, BCOP, of Mayo Clinic provides an overview of growth factor biosimilars for pharmacists amid the pandemic.
In an educational program, Julianna Merten, PharmD, BCPS, BCOP, reviews changes in practice necessitated by coronavirus disease 2019 (COVID-19) and how these affect adherence to national guidelines for the appropriate use of oncology supportive care growth factor biosimilars. This interactive program entitled "Use of Oncology Supportive Care Biosimilars During COVID-19: Clinical Strategies for Pharmacists" features an emphasis on use of these agents for treatment of neutropenia, alternative approaches to care, and economic considerations. The program is available now thorugh July 15, 2021.
How Community Oncologists Can Break Down Biosimilar Adoption Barriers
March 19th 2023On this episode of Not So Different, Mark Guyot, senior director of unity provider engagement at McKesson, gives an overview of McKesson’s real-world analysis of community oncology practices and their use of biosimilars and offers advice on overcoming adoption barriers and expanding education efforts.
Biorationality: A Dr Sarfaraz Niazi Column—A New Perspective on Biosimilars Role Within Big Pharma
March 13th 2023Sarfaraz K. Niazi, PhD, explained why Indian manufacturers aren’t bringing biosimilars to the United States and how FDA policies and procedures discourage global companies from pursuing US market entry.
White Paper Argues Increased Competition Will Improve Biosimilar Uptake, Savings
March 8th 2023A white paper touting biosimilar successes in the United States reasoned that increased market competition will help improve utilization rates, generate substantial savings, and encourage payers to cover biosimilars.
2 Clarke Drive
Cranbury, NJ 08512